SCHEMBL20485263

SCHEMBL20485263

O=C(Cc1ccc(F)cc1F)Nc1ccn(-c2ccccc2)n1

nearest known ligand 0.78

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ELOVL1 Q9BW60 11/20 0.78
▸ MAPT P10636 3/20 0.57
▸ KDM4E B2RXH2 1/20 0.55
▸ CACNA1G O43497 1/20 0.55
▸ CACNA1H O95180 1/20 0.55
▸ CACNA1I Q9P0X4 1/20 0.55
▸ TSHR P16473 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ LMNA P02545 1/20 0.47
▸ P2RX7 Q99572 1/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20485390 0.91 ELOVL1 (0.78) ELOVL1MAPTKDM4ECACNA1GCACNA1H
SCHEMBL20485258 0.89 ELOVL1 (0.75) ELOVL1MAPTKDM4ECACNA1GCACNA1H
SCHEMBL20485386 0.88 ELOVL1 (0.78) ELOVL1MAPTKDM4ECACNA1GCACNA1H
SCHEMBL20242031 0.88 ELOVL1 (1.00) ELOVL1MAPTKDM4ECACNA1GCACNA1H
SCHEMBL20485455 0.87 ELOVL1 (0.65) ELOVL1MAPTKDM4ECACNA1GCACNA1H
SCHEMBL20250016 0.86 ELOVL1 (0.86) ELOVL1MAPTKDM4ECACNA1GCACNA1H
SCHEMBL20250145 0.86 ELOVL1 (0.70) ELOVL1MAPTKDM4ECACNA1GCACNA1H
SCHEMBL20249741 0.85 ELOVL1 (0.80) ELOVL1MAPTKDM4ECACNA1GCACNA1H
SCHEMBL20485339 0.85 ELOVL1 (0.76) ELOVL1MAPTKDM4ECACNA1GCACNA1H
SCHEMBL20485270 0.83 ELOVL1 (0.82) ELOVL1MAPTKDM4ECACNA1GCACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180251431-A1 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS VERTEX PHARMACEUTICALS INCORPORATED 2018-09-06 — — US claimed
US-20180251431-A1 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS VERTEX PHARMACEUTICALS INCORPORATED 2018-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251431-A1 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS HSD17B4, CPT1A, ADH1A ELOVL1 39/4885MAPT 2013/4885KDM4E 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback